The biotech company CureVac has confirmed press releases on the issue price for the upcoming IPO on NASDAQ in the USA. The more than 13.3 million shares of the Tübingen-based biotech company will be placed at $ 16.00, which is the upper end of the price range. “In addition, the company is granting subscribers a 30-day option to purchase up to 1,999,999 additional common shares at the public offering price, less subscription discounts and commissions,” CureVac said in a release on Friday afternoon. “All shares are offered by CureVac,” the company continues.
The fresh money from the IPO is to be invested in research into a corona vaccine. Production capacities are also to be expanded. An oncology program is also to be funded. The IPO is supported by BofA Securities, Jefferies, Credit Suisse Securities as well as Berenberg and Kempen & Co. The completion of the offer is expected on August 18th, according to the Süddeutsche.
Starting today, the CureVac shares will also be traded on the US technology exchange NASDAQ. The ticker for the paper will be “CVAC”. For secondary listings in Germany, the WKN of the CureVac share is “A2P71U” and the ISIN is “NL0015436031”.